Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Update

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 5,110,000 shares, a decrease of 28.5% from the February 28th total of 7,150,000 shares. Based on an average daily trading volume, of 2,430,000 shares, the days-to-cover ratio is currently 2.1 days. Approximately 14.2% of the company's shares are sold short.

Checkpoint Therapeutics Stock Performance

Checkpoint Therapeutics stock remained flat at $4.04 during midday trading on Thursday. 3,954,612 shares of the company's stock traded hands, compared to its average volume of 2,401,524. The firm has a market cap of $197.29 million, a P/E ratio of -2.20 and a beta of 1.21. The business's 50 day moving average price is $3.38 and its 200-day moving average price is $3.30. Checkpoint Therapeutics has a one year low of $1.38 and a one year high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.47). The firm had revenue of $0.04 million for the quarter. As a group, sell-side analysts expect that Checkpoint Therapeutics will post -0.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on CKPT shares. HC Wainwright restated a "neutral" rating and issued a $4.10 target price on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th. D. Boral Capital reiterated a "buy" rating and issued a $4.80 price target on shares of Checkpoint Therapeutics in a report on Monday. Finally, Lake Street Capital restated a "hold" rating and set a $4.10 price objective (down from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th.

Insider Activity

In related news, CFO William Garrett Gray sold 74,110 shares of the business's stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the transaction, the chief financial officer now owns 1,458,644 shares in the company, valued at $5,353,223.48. The trade was a 4.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $3.15, for a total value of $32,542.65. Following the completion of the sale, the chief executive officer now owns 3,775,019 shares in the company, valued at approximately $11,891,309.85. The trade was a 0.27 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 93,674 shares of company stock valued at $336,011. 2.10% of the stock is currently owned by insiders.

Institutional Trading of Checkpoint Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CKPT. Ameriflex Group Inc. bought a new stake in Checkpoint Therapeutics during the fourth quarter valued at about $32,000. PUREfi Wealth LLC bought a new position in Checkpoint Therapeutics in the fourth quarter worth about $32,000. SBI Securities Co. Ltd. purchased a new stake in shares of Checkpoint Therapeutics during the fourth quarter valued at about $32,000. Stifel Financial Corp bought a new stake in shares of Checkpoint Therapeutics in the 4th quarter valued at about $32,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Checkpoint Therapeutics by 157.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company's stock valued at $34,000 after buying an additional 6,486 shares in the last quarter. Institutional investors own 22.00% of the company's stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.